Last $8.65 USD
Change Today -0.3824 / -4.23%
Volume 7.9K
MYOS On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

myos corp (MYOS) Key Developments

MYOS Corp. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

MYOS Corp. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company's net sales were approximately $107,000 compared to $918,000 a year ago. Loss from operations was $2,177,000 compared to $782,000 a year ago. Net loss and comprehensive income was $2,177,000 compared to $781,000 a year ago. Basic and diluted net loss per share attributable to common stockholders was $0.75 compared to $0.35 a year ago. Non-GAAP, net loss was $1,625,000 compared to $454,000 for a year ago. Non-GAAP basic and diluted net loss per share was $0.56 compared to $0.20 a year ago. For the nine months, the company's net sales were approximately $3,332,000 compared to $1,910,000 a year ago. Loss from operations was $3,601,000 compared to $2,858,000 a year ago. Net loss and comprehensive income was $3,599,000 compared to $2,854,000 a year ago. Basic and diluted net loss per share attributable to common stockholders was $1.28 compared to $1.29 a year ago. Non-GAAP, net loss was $2,267,000 compared to $1,789,000 for a year ago. Non-GAAP basic and diluted net loss per share was $0.81 compared to $0.81 a year ago.

MYOS Corporation to Report Q3, 2014 Results on Nov 14, 2014

MYOS Corporation announced that they will report Q3, 2014 results Pre-Market on Nov 14, 2014

MYOS Corporation, Q3 2014 Earnings Call, Nov 14, 2014

MYOS Corporation, Q3 2014 Earnings Call, Nov 14, 2014

MYOS Corporation Proposes Amendments to the Articles of Incorporation

MYOS Corporation at the annual meeting of the stockholders to be held on December 18, 2014, proposed amendments to the Articles of Incorporation to increase the aggregate number of authorized shares of common stock by 2,000,000 shares to 8,000,000 shares.

MYOS Corporation Announces Statistically Significant Top-Line Clinical Data Demonstrating Fortetropin's(TM) Anti-Inflammatory BioTherapeutic Properties

MYOS Corporation announced new data from its clinical trial conducted at The University of Tampa which examined the effects of Fortetropin(TM) in conjunction with modest resistance training in average men. Earlier this year MYOS reported positive data confirming that the use of Fortetropin significantly increases muscle size and lean body mass in recreationally-exercised male subjects. Further analysis of serum biomarkers from subjects in the clinical trial revealed that daily use of Fortetropin significantly decreases inflammatory cytokine levels which demonstrates Fortetropin's promising anti-inflammatory biotherapeutic properties. The double-blind, placebo-controlled trial divided forty-five participants into placebo, 6.6 grams and 19.8 grams Fortetropin daily dosing arms for a period of 12 weeks. In addition to measuring skeletal muscle growth, lean body mass, strength, and power, the study protocol also called for a series of serum panel evaluations including IFN- inflammatory cytokine screening. For subjects in the placebo group, no statistically significant changes in serum levels of IFN- were noted. However, subjects in both Fortetropin daily dosing arms experienced statistically significant decreases (p < 0.05) in serum levels of the IFN- inflammatory cytokine. IFN- is recognized as a signature pro-inflammatory cytokine protein that plays a central role in inflammation and autoimmune diseases. Excess levels of inflammatory cytokines are associated with muscle-wasting diseases such as sarcopenia and cachexia.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYOS:US $8.65 USD -0.3824

MYOS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MYOS.
View Industry Companies
 

Industry Analysis

MYOS

Industry Average

Valuation MYOS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.3x
Price/Book 4.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYOS CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.